Growth momentum Cellese recently launched P.E.A.R.L., an in-office treatment combining exosomes and PDRN, signaling product innovation and expansion of treatment offerings that can drive new client acquisition and higher AOV in aesthetics and regenerative medicine channels.

Leadership upscale New CEO Christopher Hausman with three decades in aesthetics and healthcare leadership joins Cellese, presenting an opportunity to align sales strategy with seasoned industry guidance and potential partnerships with high-end clinics and medspa networks.

Private equity backing Acquisition by ARCHIMED in 2024 positions Cellese within a PE-backed growth trajectory, suggesting access to larger distribution channels, capital for marketing scale, and collaborations with portfolio partners.

Revenue potential Current revenue range of 10-25 million places Cellese as a mid-market player with room to scale through new product launches, clinic partnerships, and direct-to-clinic programs targeting high-volume aesthetics practices.

Competitive positioning Focused on regenerative aesthetics with the AnteAGE brand and unique science-based remedies, Cellese can pursue differentiating partnerships with premium skincare retailers, clinical distributors, and specialized dermatology clinics seeking innovative, proven solutions.